CEO
Cohance Lifesciences Limited
Equibles does not estimate personal net worth.
Gunjan Singh is recorded as CEO at Cohance Lifesciences Limited. Gunjan Singh has spoken on 3 earnings calls across 1 company, most recently for Cohance Lifesciences Limited on November 6, 2026. Cohance Lifesciences Limited is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
“I will take you through our ATI Plus business, which brings together our established ATI franchise and formulations.”
“I will cover API Plus, which comprises our API and formulations businesses. Within this segment, the API business remains resilient, performing slightly ahead of our internal expectations during the quarter, with favorable pricing and an improved product mix.”
“The API Plus business reported revenues of 10.88 billion rupees in FY26, reflecting a decline of 8% year on year. The software performance was due to product-specific factors, shipment delays, and temporary disruptions at the Nacharam formulation site.”
Cohance Lifesciences Limited
CEO
Transcript header (unverified)
Cohance Lifesciences Limited
Drug Manufacturers - Specialty & Generic · Healthcare
CEO
Earnings Call for the Quarter Ended September 30, 2026
Cohance Lifesciences Limited
Earnings Call
Cohance Lifesciences Limited
Earnings Call for the Quarter Ended March 31, 2026
Cohance Lifesciences Limited
